Future cardiology最新文献_第7页

Efficacy and safety of empagliflozin in acute heart failure: a systematic review and meta-analysis. 恩格列净治疗急性心力衰竭的疗效和安全性：一项系统综述和荟萃分析。

IF 1

Future cardiology Pub Date : 2025-06-01 Epub Date: 2025-05-05 DOI: 10.1080/14796678.2025.2499374

Noman Khalid, Muhammad Adil Afzal, Muhammad Abdullah, Ata-Ul Haiy, Yezin Shamoon, Sherif Elkattawy, Muhammad Aamir Laghari, Rahul Vasudev, Shamoon E Fayez, Yasotha Rajeswaran, Gregg M Lanier, Wilbert Aronow

{"title":"Efficacy and safety of empagliflozin in acute heart failure: a systematic review and meta-analysis.","authors":"Noman Khalid, Muhammad Adil Afzal, Muhammad Abdullah, Ata-Ul Haiy, Yezin Shamoon, Sherif Elkattawy, Muhammad Aamir Laghari, Rahul Vasudev, Shamoon E Fayez, Yasotha Rajeswaran, Gregg M Lanier, Wilbert Aronow","doi":"10.1080/14796678.2025.2499374","DOIUrl":"10.1080/14796678.2025.2499374","url":null,"abstract":"Background: Acute heart failure (AHF) is leading cause of hospitalization and mortality. Empagliflozin, a Sodium Glucose Co-transporter 2 inhibitor (SGLT-2i), has demonstrated benefits in HFrEF and HFpEF, but its role in AHF remains under-explored.Objective: Assess safety and efficacy of empagliflozin in AHF.Methods: A systematic review and meta-analysis adhering to PRISMA 2020 guidelines was conducted. A search on 25 February 2025, identified Phase IIb and III randomized controlled trials (RCTs) involving adults with AHF from databases like Medline®, Cochrane CENTRAL, Embase, and ClinicalTrials.gov. Outcomes included all-cause mortality, HF rehospitalization, cardiovascular deaths, and serious adverse events. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Heterogeneity was assessed with I2 and Cochrane Q-statistic.Results: Three RCTs (n = 824) were included. Empagliflozin reduced all-cause mortality (OR: 0.47, 95% CI: 0.29-0.78, p = 0.004) and cardiovascular death (OR: 0.56, 95% CI: 0.38-0.82, p = 0.003) compared to placebo. It also lowered serious adverse events risk (OR: 0.62, 95% CI: 0.44-0.87, p = 0.005) without significantly increasing adverse effects such as acute kidney injury, diabetic ketoacidosis, hypotension, or urinary tract infections. Sensitivity analyses confirmed these findings.Conclusion: Empagliflozin reduces mortality in AHF with a favorable safety profile, highlighting need for further trials.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"495-501"},"PeriodicalIF":1.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identifying ventricular arrhythmia and sudden cardiac arrest in clinical notes of an electronic health record database. 在电子健康记录数据库的临床记录中识别室性心律失常和心脏骤停。

IF 1.6

Future cardiology Pub Date : 2025-06-01 Epub Date: 2025-05-18 DOI: 10.1080/14796678.2025.2506956

Neil Dhopeshwarkar, Charles Dharmani, Oluwatosin Fofah, Nora Tu, Nasser Khan, Tzuyung Douglas Kou, K Arnold Chan

{"title":"Identifying ventricular arrhythmia and sudden cardiac arrest in clinical notes of an electronic health record database.","authors":"Neil Dhopeshwarkar, Charles Dharmani, Oluwatosin Fofah, Nora Tu, Nasser Khan, Tzuyung Douglas Kou, K Arnold Chan","doi":"10.1080/14796678.2025.2506956","DOIUrl":"10.1080/14796678.2025.2506956","url":null,"abstract":"Aim: Validating an operational algorithm for identifying ventricular arrhythmia and sudden cardiac arrest (VA/SCA) in electronic health record (EHR) data may be useful to minimize measurement bias in studies characterizing real-world VA/SCA risk; however, validation studies require an appropriate reference standard. We aimed to assess if adequate information is documented in unstructured clinical notes of a large EHR database to serve as a reference standard for future validation studies of VA/SCA.Methods: Twenty potential VA/SCA events were randomly selected from unstructured clinical notes of a large EHR database, TriNetX Dataworks - USA. These notes were reviewed to assess if key clinical elements were documented to confirm the occurrence of VA/SCA and describe their clinical features. These included explicit documentation of an acute event, electrocardiogram (ECG) findings, urgent medical interventions, and other elements.Results: Explicit documentation of an acute event was recorded for 17 patients (85.0%) and ECG findings were documented for 15 patients (75.0%). Generally, unstructured clinical notes also contained information about signs and symptoms, care setting, medical interventions administered, and event resolution.Conclusions: The unstructured clinical notes of a large EHR database contained the information necessary to serve as a reference standard for validation studies of a VA/SCA operational algorithm in EHR data.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"593-598"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of angiotensin receptor neprilysin inhibitors in patients with STEMI: a systematic review and meta-analysis. 血管紧张素受体奈普利素抑制剂对STEMI患者的影响：系统回顾和荟萃分析。

IF 1.6

Future cardiology Pub Date : 2025-06-01 Epub Date: 2025-05-26 DOI: 10.1080/14796678.2025.2506350

Aymen Ahmed, Muhammad Umer Sohail, Muhammad Saad, Zara Naveed, Muhammad Sameer Arshad, Areesha Jawed, Adeena Musheer, Anousheh Awais Paracha, Ahmed Kamal Siddiqi, Neha Saleem Paryani, Izza Shahid, Muhammad Mustafa Memon

{"title":"Effect of angiotensin receptor neprilysin inhibitors in patients with STEMI: a systematic review and meta-analysis.","authors":"Aymen Ahmed, Muhammad Umer Sohail, Muhammad Saad, Zara Naveed, Muhammad Sameer Arshad, Areesha Jawed, Adeena Musheer, Anousheh Awais Paracha, Ahmed Kamal Siddiqi, Neha Saleem Paryani, Izza Shahid, Muhammad Mustafa Memon","doi":"10.1080/14796678.2025.2506350","DOIUrl":"10.1080/14796678.2025.2506350","url":null,"abstract":"Background: ST-segment elevation myocardial infarction (STEMI) is responsible for high morbidity and mortality rates globally. Although the use of angiotensin-converting enzyme inhibitors (ACEIs) remains the cornerstone treatment for patients with STEMI, the use of angiotensin-receptor neprilysin inhibitors (ARNIs) may offer better outcomes than ACEIs. This meta-analysis compares the efficacy and safety of ARNIs versus ACEIs in patients with STEMI.Methods: Randomized controlled trials (RCTs) were pooled from PubMed and Cochrane databases. A random-effects model calculated risk ratios (RRs) and weighted mean differences (WMDs) with 95% confidence intervals (CIs).Results: Five trials (n = 4,915) were included. ARNIs significantly reduced major adverse cardiovascular events (MACE) (RR: 0.66, 95% CI [0.50, 0.86]; p = 0.002) and hospitalizations for heart failure (HHF) (RR: 0.67, 95% CI [0.49, 0.92]; p = 0.01). ARNIs also improved left ventricular ejection fraction (LVEF) (WMD: 2.60, 95% CI[1.53, 3.68]; p < 0.00001) and lowered NT-proBNP levels (WMD: -268.89, 95% CI[-422.35, -115.42]; p = 0.0006). No significant differences were observed in recurrent myocardial infarction, cardiovascular death, or safety outcomes - except for hypotension, which was significantly more common with ARNI use.Conclusions: ARNI therapy reduces MACE, HHF, and NT-proBNP levels and improves LVEF in patients with STEMI without increasing safety risks, except for hypotension. Further RCTs are needed to confirm these findings.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"599-609"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: a plain language summary. 转甲状腺素淀粉样变合并心肌病患者用乌曲西兰治疗：一个简单的语言总结。

IF 1.6

Future cardiology Pub Date : 2025-06-01 Epub Date: 2025-05-15 DOI: 10.1080/14796678.2025.2493019

Marianna Fontana, Julian D Gillmore, Ronald M Witteles, Ben Laryea, Marc Dworkin, Ann Payne, Fran Kochman, Satish Eraly, Mathew S Maurer

引用次数: 0

The clinical role of closed loop stimulation pacemakers in the treatment of patients with sinus node dysfunction: a review. 闭环刺激起搏器治疗窦结功能障碍的临床作用综述。

IF 1.6

Future cardiology Pub Date : 2025-06-01 Epub Date: 2025-05-19 DOI: 10.1080/14796678.2025.2507464

Alessio Gargaro, Gianluca Biancalana, Giovanni Luca Botto, Michele Brignole

{"title":"The clinical role of closed loop stimulation pacemakers in the treatment of patients with sinus node dysfunction: a review.","authors":"Alessio Gargaro, Gianluca Biancalana, Giovanni Luca Botto, Michele Brignole","doi":"10.1080/14796678.2025.2507464","DOIUrl":"10.1080/14796678.2025.2507464","url":null,"abstract":"Sinus bradycardia, sinoatrial block, sinus arrest, and bradycardia-tachycardia syndrome are manifestations of intermittent or persistent sinus node dysfunctions (SNDs). SND is classified as intrinsic, when related to an anatomic disease of sinoatrial cells, or extrinsic, when bradycardia is caused by inappropriate vagal outflow. Chronotropic incompetence is often associated with SND, especially in elderly patients. When symptoms are related to SND, pacemaker implantation is the recommended therapy, and rate-adaptive pacing modes are often preferred in cases of chronotropic incompetence. Closed-Loop Stimulation (CLS) is a rate-adaptive system based on continuous evaluation of contractility and contraction speed through the analysis of right-ventricular unipolar impedance trends during the systole of each cardiac cycle. An increase in contractility or contraction speed modifies the impedance trends, to which the CLS algorithm responds by adapting the pacing rate, and thereby heart rate and cardiac output. Therefore, CLS is integrated into the autonomic mechanisms of cardiac output regulation. This feature has drawn interest in the use of CLS in several forms of SND, from the treatment of intrinsic bradycardias to the prevention of vasovagal syncope and device-detected atrial fibrillation. We will examine the working principle of CLS and review the results of recent clinical investigations.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"567-578"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SGLT2 inhibitors across the acute cardiac care spectrum: insights and perspectives. 急性心脏护理谱中的SGLT2抑制剂：见解和观点。

IF 1

Future cardiology Pub Date : 2025-06-01 Epub Date: 2025-05-11 DOI: 10.1080/14796678.2025.2503666

Maurizio Bertaina, Alessandro Galluzzo, Carla Carbonaro, Alessandra Marzulli, Chiara Calcagnile, Pierluigi Sbarra, Luca Franchin, Giacomo Giovanni Boccuzzi, Mario Iannaccone

{"title":"SGLT2 inhibitors across the acute cardiac care spectrum: insights and perspectives.","authors":"Maurizio Bertaina, Alessandro Galluzzo, Carla Carbonaro, Alessandra Marzulli, Chiara Calcagnile, Pierluigi Sbarra, Luca Franchin, Giacomo Giovanni Boccuzzi, Mario Iannaccone","doi":"10.1080/14796678.2025.2503666","DOIUrl":"10.1080/14796678.2025.2503666","url":null,"abstract":"This review examines the evolving role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in acute cardiac care. Originally developed as antidiabetic agents, SGLT2i have demonstrated significant and early benefits in chronic heart failure by reducing hospitalizations and cardiovascular mortality across all the ejection fraction spectrum. Recent evidence now suggests that these agents may also offer advantages in acute settings, including acute decompensated heart failure (ADHF) and post - acute myocardial infarction (AMI). Several clinical trials have explored early SGLT2i initiation during hospitalization, reporting improvements in diuretic efficiency, cardiac biomarkers, and favorable remodeling, without notable safety concerns. The present review discusses the multifaceted mechanisms underlying these benefits, which include osmotic diuresis, modulation of neurohormonal activation, anti-inflammatory effects, and direct myocardial protection. Together, these actions not only facilitate decongestion and renal preservation but also enhance cardiac energetics. Current data are promising and support a pivotal role of a SGLT2i as a therapeutic strategy in the whole acute cardiac care setting for their short and long-term benefit. Future research is essential to validate these findings and refine the best patients to be treated with early SGLT2i implementation in the acute cardiac care spectrum.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"515-525"},"PeriodicalIF":1.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Favorable cardiac remodeling in response to treatment in obstructive hypertrophic cardiomyopathy: a current appraisal. 对梗阻性肥厚性心肌病治疗的有利心脏重塑：当前评估。

IF 1

Future cardiology Pub Date : 2025-06-01 Epub Date: 2025-06-03 DOI: 10.1080/14796678.2025.2501466

Susan Keen, Milind Y Desai

{"title":"Favorable cardiac remodeling in response to treatment in obstructive hypertrophic cardiomyopathy: a current appraisal.","authors":"Susan Keen, Milind Y Desai","doi":"10.1080/14796678.2025.2501466","DOIUrl":"10.1080/14796678.2025.2501466","url":null,"abstract":"Hypertrophic cardiomyopathy is a heterogenous genetic condition caused by myocyte disarray with varying degrees of interstitial fibrosis. Traditional management strategies focused on symptom mitigation and sudden cardiac death prevention among high-risk patients. The only disease-modifying treatments have historically been septal reduction therapy or heart transplantation. However, cardiac myosin inhibitors have emerged as promising novel pharmacotherapies. Emerging evidence indicates that cardiac myosin inhibitors as well as surgical myectomy result in not only symptomatic benefit and reduction in left ventricular outflow tract obstruction, but also positive cardiac remodeling including reduction in left ventricular mass and maximum wall thickness, improved left ventricular diastolic parameters, reduced left atrial volumes, and improved left atrial strain. The long-term durability and clinical significance of these findings require further study. In this article, we will review the existing evidence of favorable reverse remodeling conferred by cardiac myosin inhibitors and surgical myectomy.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"527-537"},"PeriodicalIF":1.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A clinician's guide to cardiovascular MRI referrals: a practical guide of ESC recommendations. 临床医生心血管MRI转诊指南：ESC推荐的实用指南。

IF 1

Future cardiology Pub Date : 2025-06-01 Epub Date: 2025-04-01 DOI: 10.1080/14796678.2025.2485787

Nicola Ciocca, Henri Lu, Georgios Tzimas, Niccolò Maurizi, Ioannis Skalidis, Mark Colin Gissler, Pierre Monney, Christoph Gräni, Yin Ge, Panagiotis Antiochos

引用次数: 0

Threading a needle: percutaneous closure of an incompletely ligated left atrial appendage. 穿刺针：经皮缝合不完全结扎的左心房附件。

IF 1

Future cardiology Pub Date : 2025-06-01 Epub Date: 2025-04-29 DOI: 10.1080/14796678.2025.2499449

Abhinav Sood, Channing Pezet, Fnu Parul, Anubhav Sood, Jagadeesh Kalavakunta, Vishal Gupta

引用次数: 0

Advancing antithrombotic therapies for left ventricular assist devices: challenges, innovations, and future perspectives. 推进左心室辅助装置的抗血栓治疗：挑战、创新和未来展望。

IF 1.6

Future cardiology Pub Date : 2025-06-01 Epub Date: 2025-04-12 DOI: 10.1080/14796678.2025.2491196

Ameesh Isath, Michael Pfeffer, Mandeep R Mehra

引用次数: 0